The US Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare ...

The US Food and Drug Administration (FDA) granted accelerated approval to the oral selective estrogen receptor degrader (SERD) camizestrant (Etcamah) in combination with a cyclin- ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...

The US Food and Drug Administration has approved daraxonrasib (Rasonque), a first-in-class once-daily oral tablet targeting ...

The University of Kansas Cancer Center The University of South Alabama, Mitchell Cancer Institute The University of Texas MD Anderson Cancer Center The Winthrop P. Rockefeller Cancer Institute at the ...

Beth Sandy, CRNP, of Penn Medicine discusses therapeutic advances in thoracic oncology, toxicity management, and overcoming ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

The US Food and Drug Administration (FDA) has approved the HER2-directed bispecific antibody zanidatamab-hrii (Ziihera) as a ...

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

NP Theresa Stukus and NP Nelli Zafman discuss key considerations when interpreting emerging frontline clinical trial data for ...

C, discussed the collaborative care model and the vital role of PAs in managing day-to-day oncology care. Physician ...

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- ...